AR052871A1 - Una sintesis exo-selectiva de analogos de himbacina - Google Patents
Una sintesis exo-selectiva de analogos de himbacinaInfo
- Publication number
- AR052871A1 AR052871A1 ARP060100128A ARP060100128A AR052871A1 AR 052871 A1 AR052871 A1 AR 052871A1 AR P060100128 A ARP060100128 A AR P060100128A AR P060100128 A ARP060100128 A AR P060100128A AR 052871 A1 AR052871 A1 AR 052871A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- group
- exo
- selective synthesis
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- FMPNFDSPHNUFOS-LPJDIUFZSA-N himbacine Chemical class C(/[C@@H]1[C@H]2CCCC[C@@H]2C[C@@H]2C(=O)O[C@H]([C@H]12)C)=C\[C@H]1CCC[C@H](C)N1C FMPNFDSPHNUFOS-LPJDIUFZSA-N 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 238000007363 ring formation reaction Methods 0.000 abstract 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- -1 OR8 Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
Reivindicacion 1: Un proceso para preparar el compuesto de formula (1) a través de ciclacion, comprendiendo dicha ciclacion los pasos de: a) calentar el compuesto de formula (2) en un solvente hasta una temperatura elevada; y b) tratar con una base, en el que el compuesto de formula (2) está dado por la formula esta dado, en la cual: R1 se selecciona del grupo formado por OR4 y NR5R6, R2 y R3 se seleccionan, en forma independiente, del grupo formado por H, NHR7, OR8, NHC(O)R4, y NO2, o R2 y R3, tomados junto con el carbono al cual están unidos, forman un anillo heterocíclico de 5 a 7 miembros que contiene 1 a 3 heteroátomos; y R4, R5, R6, R7, y R8 se seleccionan, cada uno de manera independiente, del grupo formado por H, grupos alquilo, alquenilo, alquinilo, alcoxi, cicloalquilo, arilo, alquilarilo, arilalquilo, y heteroarilo, o cuando R1 es NR5R6 entonces R5 y R6 pueden, junto con el nitrogeno al cual están unidos, formar un anillo heterocíclico de 3 a 6 miembros que contiene 1 a 3 heteroátomos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64442805P | 2005-01-14 | 2005-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR052871A1 true AR052871A1 (es) | 2007-04-11 |
Family
ID=36293324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100128A AR052871A1 (es) | 2005-01-14 | 2006-01-12 | Una sintesis exo-selectiva de analogos de himbacina |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7772276B2 (es) |
| EP (2) | EP2399912B1 (es) |
| JP (4) | JP4775971B2 (es) |
| CN (2) | CN105175387A (es) |
| AR (1) | AR052871A1 (es) |
| CA (1) | CA2594807A1 (es) |
| ES (1) | ES2535534T3 (es) |
| MX (1) | MX2007008622A (es) |
| SG (1) | SG158884A1 (es) |
| WO (1) | WO2006076452A2 (es) |
| ZA (3) | ZA200705787B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| CA2594807A1 (en) * | 2005-01-14 | 2006-07-20 | Schering Corporation | An exo-selective synthesis of himbacine analogs |
| CA2594871C (en) * | 2005-01-14 | 2015-04-07 | Schering Corporation | Exo- and diastereo- selective syntheses of himbacine analogs |
| ES2398502T3 (es) | 2007-10-24 | 2013-03-19 | Merck Sharp & Dohme Corp. | Procedimiento sintético de alta pureza para la preparación de intermediarios de éster de ácido dodecahidro-nafto-furanil carbámico |
| JP5861884B2 (ja) * | 2012-03-29 | 2016-02-16 | 荒川化学工業株式会社 | エキソ型ノルボルネン化合物の製造方法 |
| CN106749201A (zh) * | 2015-11-25 | 2017-05-31 | 博瑞生物医药（苏州）股份有限公司 | 一种沃拉帕沙及其中间体的制备方法 |
| CN107540564B (zh) * | 2016-06-27 | 2020-05-22 | 正大天晴药业集团股份有限公司 | 沃拉帕沙中间体的制备方法 |
| CN106699712B (zh) * | 2016-12-05 | 2019-03-01 | 上海博志研新药物技术有限公司 | 沃拉帕沙中间体及其制备方法 |
| CN106866450B (zh) * | 2017-01-13 | 2019-01-11 | 阜阳欣奕华材料科技有限公司 | 硫酸沃拉帕沙中间体的制备方法 |
| CN108658910B (zh) * | 2017-03-29 | 2020-11-03 | 北京新领先医药科技发展有限公司 | 一种沃拉帕沙中间体1-α的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063847A (en) * | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| SK285153B6 (sk) * | 1997-11-25 | 2006-07-07 | Schering Corporation | Heterocyklickou skupinou substituovaná tricyklická zlúčenina, farmaceutický prostriedok obsahujúci túto zlúčeninu a jej použitie |
| CZ20024098A3 (cs) * | 2000-06-15 | 2003-05-14 | Schering Corporation | Látky, antagonizující receptor thrombinu |
| US7235567B2 (en) | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| MY139335A (en) * | 2001-10-18 | 2009-09-30 | Schering Corp | Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists |
| ATE455774T1 (de) * | 2002-04-16 | 2010-02-15 | Schering Corp | Trizyklische thrombinrezeptorantagonisten |
| DE10317816A1 (de) | 2003-04-16 | 2004-11-04 | Claas Selbstfahrende Erntemaschinen Gmbh | Feldhäcksler mit positionierbarer Fahrerkabine |
| MX2007008630A (es) | 2005-01-14 | 2007-09-12 | Schering Corp | Preparacion de alcohol propargilico quiral y ester intermediario de analogos de himbacina. |
| US7541471B2 (en) * | 2005-01-14 | 2009-06-02 | Schering Corporation | Synthesis of himbacine analogs |
| CA2594871C (en) * | 2005-01-14 | 2015-04-07 | Schering Corporation | Exo- and diastereo- selective syntheses of himbacine analogs |
| CA2594807A1 (en) * | 2005-01-14 | 2006-07-20 | Schering Corporation | An exo-selective synthesis of himbacine analogs |
| AR061727A1 (es) * | 2006-06-30 | 2008-09-17 | Schering Corp | Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato |
| JP5099563B2 (ja) * | 2006-06-30 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | ３−（５−ニトロシクロヘキサ−１−エニル）アクリル酸およびそのエステルの合成 |
-
2006
- 2006-01-12 CA CA002594807A patent/CA2594807A1/en not_active Abandoned
- 2006-01-12 ES ES11178689.3T patent/ES2535534T3/es not_active Expired - Lifetime
- 2006-01-12 JP JP2007551361A patent/JP4775971B2/ja not_active Expired - Fee Related
- 2006-01-12 EP EP11178689.3A patent/EP2399912B1/en not_active Expired - Lifetime
- 2006-01-12 AR ARP060100128A patent/AR052871A1/es not_active Application Discontinuation
- 2006-01-12 CN CN201510616482.8A patent/CN105175387A/zh active Pending
- 2006-01-12 EP EP06718128.9A patent/EP1846385B1/en not_active Expired - Lifetime
- 2006-01-12 MX MX2007008622A patent/MX2007008622A/es active IP Right Grant
- 2006-01-12 CN CNA200680007889XA patent/CN101137636A/zh active Pending
- 2006-01-12 SG SG201000273-1A patent/SG158884A1/en unknown
- 2006-01-12 US US11/330,521 patent/US7772276B2/en active Active
- 2006-01-12 WO PCT/US2006/001015 patent/WO2006076452A2/en not_active Ceased
-
2007
- 2007-07-13 ZA ZA2007/05787A patent/ZA200705787B/en unknown
-
2010
- 2010-06-30 US US12/827,000 patent/US8138180B2/en not_active Expired - Lifetime
- 2010-12-17 JP JP2010282278A patent/JP2011052026A/ja not_active Withdrawn
-
2011
- 2011-05-17 JP JP2011110863A patent/JP2011153160A/ja active Pending
- 2011-07-15 ZA ZA2011/05256A patent/ZA201105256B/en unknown
-
2012
- 2012-02-10 US US13/370,768 patent/US8273790B2/en not_active Expired - Fee Related
- 2012-08-02 US US13/564,966 patent/US20120302745A1/en not_active Abandoned
- 2012-08-15 ZA ZA2012/06140A patent/ZA201206140B/en unknown
-
2014
- 2014-08-07 JP JP2014161055A patent/JP2015007072A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006076452A3 (en) | 2007-04-05 |
| JP2015007072A (ja) | 2015-01-15 |
| US20060217422A1 (en) | 2006-09-28 |
| EP2399912B1 (en) | 2015-02-25 |
| US20120302745A1 (en) | 2012-11-29 |
| JP2011052026A (ja) | 2011-03-17 |
| ZA200705787B (en) | 2013-09-25 |
| EP1846385A2 (en) | 2007-10-24 |
| SG158884A1 (en) | 2010-02-26 |
| EP2399912A2 (en) | 2011-12-28 |
| EP2399912A3 (en) | 2012-03-28 |
| CN101137636A (zh) | 2008-03-05 |
| US20120142914A1 (en) | 2012-06-07 |
| US8273790B2 (en) | 2012-09-25 |
| US7772276B2 (en) | 2010-08-10 |
| CN105175387A (zh) | 2015-12-23 |
| WO2006076452A8 (en) | 2007-08-23 |
| CA2594807A1 (en) | 2006-07-20 |
| ES2535534T3 (es) | 2015-05-12 |
| EP1846385B1 (en) | 2013-07-31 |
| JP2011153160A (ja) | 2011-08-11 |
| US20100267947A1 (en) | 2010-10-21 |
| ZA201105256B (en) | 2012-03-28 |
| JP4775971B2 (ja) | 2011-09-21 |
| WO2006076452A2 (en) | 2006-07-20 |
| MX2007008622A (es) | 2007-09-11 |
| US8138180B2 (en) | 2012-03-20 |
| JP2008526974A (ja) | 2008-07-24 |
| ZA201206140B (en) | 2012-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2515194T3 (es) | Derivados de pirrolidina | |
| CO6140033A2 (es) | Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia | |
| PE20120172A1 (es) | Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide | |
| AR113748A1 (es) | Proceso estereoselectivo para preparar derivados de piridona policíclicos sustituidos | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| AR065471A1 (es) | Proceso para la preparacion de ciertas sulfiliminas sustituidas | |
| Abels et al. | A General Strategy for the Catalytic, Highly Enantio‐and Diastereoselective Synthesis of Indolizidine‐Based Alkaloids | |
| PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
| AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
| CO6251264A2 (es) | Derivados de 1-ciano ciclopropilo como inhibidores de la captesina k | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| AR052871A1 (es) | Una sintesis exo-selectiva de analogos de himbacina | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| CO6640266A2 (es) | Proceso para preparar derivados de dihidropirrol | |
| ECSP10010415A (es) | Compuestos novedosos que son inhibidores de erk | |
| CO5690643A2 (es) | Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos | |
| AR048669A1 (es) | Derivados biciclicos de bisamida | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| AR042827A1 (es) | Compuestos de furano condensados | |
| AR045868A1 (es) | Proceso para preparar compuestos de ocarbamoilo en presencia de grupo amina activa | |
| NZ715847A (en) | New indole and pyrrole derivatives useful as bcl-2 inhibitors, a process for their preparation and pharmaceutical compositions containing them | |
| AR049418A1 (es) | Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes. | |
| AR072793A1 (es) | Compuestos de aril isoxazol con actividades antitumorales | |
| CO6260069A2 (es) | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa | |
| AR042362A1 (es) | Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |